We are conducting system maintenance, which may temporarily affect some services and our ability to answer phone calls. For urgent queries, please contact us via email using the addresses on our contact page. We appreciate your patience and are working to restore full services promptly. Thank you for your cooperation!

We are conducting system maintenance, which may temporarily affect some services and our ability to answer phone calls. For urgent queries, please contact us via email using the addresses on our contact page. We appreciate your patience and are working to restore full services promptly. Thank you for your cooperation!

Resmed Inc DRC

Healthcare AU RMD

34.45AUD
0.10(0.29%)

Last update at 2024-10-08T05:11:00Z

Day Range

34.2034.49
LowHigh

52 Week Range

20.6937.99
LowHigh

Fundamentals

  • Previous Close 34.35
  • Market Cap51073.56M
  • Volume512870
  • P/E Ratio34.76
  • Dividend Yield0.90%
  • EBITDA1533.54M
  • Revenue TTM4685.30M
  • Revenue Per Share TTM7.97
  • Gross Profit TTM 2386.06M
  • Diluted EPS TTM1.00

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax 1101.66M 960.48M 883.66M 733.09M 518.85M
Minority interest - - - - -
Net income 897.56M 897.56M 474.50M 474.50M 404.59M
Selling general administrative 874.00M 739.37M 670.39M 676.69M 645.01M
Selling and marketing expenses - - - - -
Gross profit 2355.66M 2024.31M 1839.10M 1717.79M 1536.59M
Reconciled depreciation 197.56M 193.84M 191.52M 181.37M 150.79M
Ebit 1141.97M 1000.29M 921.02M 808.46M 692.71M
Ebitda 1339.54M 1194.13M 1112.54M 989.83M 843.50M
Depreciation and amortization 197.56M 193.84M 191.52M 181.37M 150.79M
Non operating income net other - - - - -
Operating income 1131.87M 1000.29M 903.68M 809.66M 579.26M
Other operating expenses 3071.00M 2577.84M 2284.47M 2147.95M 1970.59M
Interest expense - 0.00000M 23.99M 40.38M 36.16M
Tax provision 204.11M 181.05M 409.16M 111.41M 108.25M
Interest income 44.72M 43.00M 34.83M 63.08M 47.98M
Net interest income -47.37900M -22.31200M -23.62700M -39.35600M -33.85700M
Extraordinary items - - - - -6.00000M
Non recurring - - - - -
Other items - - - - -
Income tax expense 204.11M 181.05M 409.16M 111.41M 114.25M
Total revenue 4222.99M 3578.13M 3196.82M 2957.01M 2606.57M
Total operating expenses 1203.66M 1024.03M 926.75M 908.73M 900.60M
Cost of revenue 1867.33M 1553.82M 1357.72M 1239.23M 1069.99M
Total other income expense net -2.95400M -17.49100M -5.06200M -36.61500M -83.28200M
Discontinued operations - - - - -
Net income from continuing ops 897.56M 779.44M 474.50M 621.67M 404.59M
Net income applicable to common shares 897.56M 779.44M 474.50M 621.67M 404.59M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 6872.39M 6751.71M 5095.85M 4728.12M 4587.38M
Intangible assets 485.90M 552.34M 345.94M 392.58M 448.17M
Earning assets - - - - -
Other current assets 180.01M 437.02M 337.91M 208.15M 168.75M
Total liab 2008.35M 2621.80M 1735.10M 1842.45M 2090.35M
Total stockholder equity 4864.04M 4129.90M 3360.75M 2885.68M 2497.03M
Deferred long term liab - - - - -
Other current liab 485.19M 875.77M 779.23M 1257.12M 335.11M
Common stock 0.59M 0.59M 0.59M 0.58M 0.58M
Capital stock 0.59M 0.59M 0.59M 0.58M 0.58M
Retained earnings 4991.65M 4253.02M 3613.74M 3079.64M 2832.99M
Other liab - 315.19M 160.03M 172.55M 221.57M
Good will 2842.05M 2770.30M 1936.44M 1927.90M 1890.32M
Other assets - 261.31M 202.29M 200.66M 145.60M
Cash 238.36M 227.89M 273.71M 295.28M 463.16M
Cash and equivalents - - 273.71M 295.28M 463.16M
Total current liabilities 910.65M 758.53M 689.30M 911.77M 602.76M
Current deferred revenue 152.55M 138.07M 108.67M 109.61M 98.62M
Net debt 635.57M 1352.02M 643.84M 498.44M 836.11M
Short term debt 35.18M 31.82M 31.77M 35.59M 33.25M
Short long term debt 9.90M 9.90M 9.92M 12.00M 11.99M
Short long term debt total 873.93M 1579.91M 917.55M 793.72M 1299.26M
Other stockholder equity 123.34M 148.83M 59.18M -1.05700M -52.56200M
Property plant equipment - 665.81M 630.50M 592.07M 535.68M
Total current assets 2357.72M 2367.83M 1931.48M 1574.76M 1523.46M
Long term investments - - - - -
Net tangible assets - 807.26M 1078.37M 565.20M 158.53M
Short term investments - - - - -
Net receivables 837.27M 704.91M 575.95M 614.29M 474.64M
Long term debt 697.31M 1431.23M 765.33M 643.35M 1164.13M
Inventory 822.25M 998.01M 743.91M 457.03M 416.92M
Accounts payable 237.73M 150.76M 159.25M 138.01M 135.79M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -251.52900M -272.52800M -312.74700M -193.48700M -283.98200M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - -1623.25600M -1623.25600M
Accumulated amortization - - - - -
Non currrent assets other 284.00M 395.43M 251.49M 240.82M 189.74M
Deferred long term asset charges - - - - -
Non current assets total 4514.68M 4383.88M 3164.38M 3153.37M 3063.92M
Capital lease obligations 166.72M 138.77M 142.31M 138.36M 123.14M
Long term debt total - - 765.33M 643.35M 1164.13M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -1159.84500M -13.92200M -21.78800M -31.61600M -46.71700M
Change to liabilities 31.34M -247.63200M 210.71M -23.42400M -27.27800M
Total cashflows from investing activities -1159.84500M -229.91800M -158.46200M -179.86100M -1075.70600M
Net borrowings 665.00M 122.00M -522.00000M -94.01200M 807.49M
Total cash from financing activities 422.87M -128.36300M -764.63200M -317.28600M 580.64M
Change to operating activities -138.12500M -168.10900M -58.15400M -58.99900M -47.57500M
Net income 897.56M 779.44M 474.50M 621.67M 404.59M
Change in cash -45.81900M -21.56800M -167.87800M 316.03M -41.57300M
Begin period cash flow 273.71M 295.28M 463.16M 147.13M 188.70M
End period cash flow 227.89M 273.71M 295.28M 463.16M 147.13M
Total cash from operating activities 693.30M 351.15M 736.72M 802.25M 459.05M
Issuance of capital stock 49.14M 47.38M 37.79M 48.18M 36.73M
Depreciation 197.56M 193.84M 191.52M 181.37M 150.79M
Other cashflows from investing activities -1025.84500M -17.17600M 19.22M -14.39700M -0.26400M
Dividends paid -258.27600M 245.34M -245.34100M -226.71300M -225.09300M
Change to inventory -248.83300M -311.68100M -21.95400M -69.88100M -84.18800M
Change to account receivables -106.51100M 19.35M -129.19500M 54.38M -18.01300M
Sale purchase of stock 1070.00M 288.00M 90.00M 1190.00M -22.84400M
Other cashflows from financing activities -32.99200M -52.40600M -53.70900M -46.36300M 1490.22M
Change to netincome 60.31M 85.94M 74.39M 97.13M 80.72M
Capital expenditures 134.00M 156.04M 116.83M 105.94M 77.34M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -462.12700M -708.07600M 1.41M -97.92100M -177.05400M
Stock based compensation 71.14M 65.26M 65.26M 63.93M 57.56M
Other non cash items -11.05000M 20.69M 8.67M -0.00700M -0.28600M
Free cash flow 559.30M 195.11M 619.89M 696.32M 381.71M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
RMD
Resmed Inc DRC
0.10 0.29% 34.45 34.76 27.10 10.90 7.29 7.62 23.39
FPH
Fisher & Paykel Healthcare Corporation Limited
0.61 1.94% 32.00 155.38 59.17 10.93 11.78 11.74 56.04
ANN
Ansell Ltd
0.11 0.34% 32.65 37.85 18.42 2.90 1.72 1.98 15.86
NAN
Nanosonics Ltd
-0.08 2.16% 3.62 92.25 125.00 6.58 6.22 5.90 46.63
TRJ
Trajan Group Holdings Ltd
-0.02 1.63% 1.21 - 178.57 1.22 1.86 1.53 21.80

Reports Covered

Stock Research & News

Profile

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Resmed Inc DRC

9001 Spectrum Center Boulevard, San Diego, CA, United States, 92123

Key Executives

Name Title Year Born
Dr. Peter C. Farrell A.M., AM, B.E., BE (Hons), Ph.D., ScD Founder & Non-Exec. Chairman 1942
Mr. Michael J. Farrell BE, MBA, SM CEO & Director 1972
Mr. Robert A. Douglas Pres & COO 1960
Mr. Brett A. Sandercock Chief Financial Officer 1967
Mr. David B. Pendarvis Chief Admin. Officer, Global Gen. Counsel & Corp. Sec. 1959
Mr. Kaushik Ghoshal Pres of SaaS Bus. 1968
Ms. Urvashi Tyagi Chief Technology Officer NA
Ms. Constance C. Bienfait Director of Investor Relations NA
Ms. Amy Wakeham VP of Investor Relations & Corp. Communications NA
Ms. Vered Keisar Chief People Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.